Aranidipine: Difference between revisions

{{Short description|Antihypertensive drug of the calcium channel blocker class}}

| verifiedrevid = 458034815

| alt = Skeletal formula of aranidipine

| image2 = Aranidipine-3D-balls.png

| alt2 = Ball-and-stick model of the aranidipine molecule

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| ChEMBL = 2104030

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 2139

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = NCUCGYYHUFIYNU-UHFFFAOYSA-N

'''Aranidipine''' ([[International Nonproprietary Name|INN]], trade name '''Sapresta''') is a [[calcium channel blocker]]. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.<ref>{{cite web |title=Aranidipine |url=https://pubchem.ncbi.nlm.nih.gov/compound/aranidipine#section=Top |website=PubMed |access-date=23 December 2018}}</ref><ref>{{cite book | vauthors = Gelatsis P | chapter = To Market, to Market – 1996| veditors = Bristol JA, Robertson DW, Doherty AM, Hagmann WK, Plattner JJ, Wong WW, Trainor GL |title=Annual Reports in Medicinal Chemistry |date=1997 |publisher=Academic Press |location=San Diego |isbn=978-0-08-058376-1 |page=306 | chapter-url=https://books.google.com/books?id=oJY8LrP_JysC&dq=Aranidipine&pg=PA306}}</ref>

==References==

{{Reflist}}

[[Category:Nitrobenzene derivatives]]